Spots Global Cancer Trial Database for pancreatic adenocarcinoma resectable
Every month we try and update this database with for pancreatic adenocarcinoma resectable cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03697239 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) | NCT03410030 | Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreas Metast... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | HonorHealth Research Institute | |
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer | NCT01715142 | Pancreatic Aden... Pancreatic Aden... Pancreatic Aden... | Gemcitabine Abraxane | 18 Years - | Erasme University Hospital | |
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03697239 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03908333 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | Medical College of Wisconsin | |
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03908333 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | Medical College of Wisconsin | |
A Pilot Study of IRE for Resectable Pancreatic Cancer | NCT03337997 | Pancreatic Aden... | Irreversible El... | 18 Years - 75 Years | University of Saskatchewan | |
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | NCT03697239 | Metastatic Panc... Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreatic Meta... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | University of California, San Diego | |
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) | NCT03410030 | Pancreatic Canc... Pancreas Cancer Pancreatic Aden... Pancreatic Duct... Pancreas Metast... | Ascorbic Acid Paclitaxel prot... Cisplatin Gemcitabine | 18 Years - | HonorHealth Research Institute | |
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer | NCT01715142 | Pancreatic Aden... Pancreatic Aden... Pancreatic Aden... | Gemcitabine Abraxane | 18 Years - | Erasme University Hospital | |
A Pilot Study of IRE for Resectable Pancreatic Cancer | NCT03337997 | Pancreatic Aden... | Irreversible El... | 18 Years - 75 Years | University of Saskatchewan | |
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer | NCT01713218 | Pancreatic Aden... | gemcitabine Vismodegib Neoadjuvant che... | 18 Years - | Erasme University Hospital |